We are live on ! Find out more
NVO

Novo Nordisk

506 hedge funds and large institutions have $10.7B invested in Novo Nordisk in 2015 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 181 increasing their positions, 179 reducing their positions, and 42 closing their positions.

New
Increased
Maintained
Reduced
Closed

342% more call options, than puts

Call options by funds: $36.4M | Put options by funds: $8.25M

78% more funds holding in top 10

Funds holding in top 10: 1832 (+14)

33% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 42

25% more capital invested

Capital invested by funds: $8.53B → $10.7B (+$2.16B)

1% more repeat investments, than reductions

Existing positions increased: 181 | Existing positions reduced: 179

1% more funds holding

Funds holding: 501506 (+5)

0.11% less ownership

Funds ownership: 19.06%18.96% (-0.11%)

Holders
506
Holders Change
+5
Holders Change %
+1%
% of All Funds
13.42%
Holding in Top 10
32
Holding in Top 10 Change
+14
Holding in Top 10 Change %
+77.78%
% of All Funds
0.85%
New
56
Increased
181
Reduced
179
Closed
42
Calls
$36.4M
Puts
$8.25M
Net Calls
+$28.2M
Net Calls Change
+$28.3M

NVO Hedge Fund Activity: Q1 2015 in Review

506 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q1 2015, worth a combined $10.7B — up 25% from $8.53B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new NVO positions and 42 closed out — a net gain of 14 holders — while 181 added to existing stakes and 179 trimmed.

The largest buyer was Ameriprise, adding an estimated $181M. The largest seller was Arrowstreet Capital, cutting an estimated $114M.

  • 506 institutional investors held Novo Nordisk (NVO) as of Q1 2015, up from 501 in Q4 2014.
  • Funds reported $10.7B of Novo Nordisk stock for Q1 2015, up 25% quarter-over-quarter.
  • 56 funds opened new Novo Nordisk positions in Q1 2015 and 42 closed out, a net change of +14 holders.
  • The largest Novo Nordisk buyer in Q1 2015 was Ameriprise, an estimated $181M added.
  • The largest Novo Nordisk seller in Q1 2015 was Arrowstreet Capital, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2015.